Posted by Michael Wonder on 10 Jan 2024
Leqembi approved for the treatment of Alzheimer's disease in China
9 January 2024 - BioArctic's partner Eisai announced today that Leqembi (lecanemab-irmb) has been approved in China as a treatment for mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia.
China is the third country to grant marketing approval, following the traditional approval in the United States in July 2023 and Japanese approval in September 2023. Eisai's preparations for the Chinese launch in the of the third quarter 2024 are underway.
